Natco Pharma invests $14 million more in eGenesis via convertible notes
- Natco Pharma invests additional $14 million in eGenesis, Inc.
- Investment structured as convertible promissory notes at 8% interest
- Subsidiaries NATCO Canada ($9.5m) and NATCO South Africa ($4.5m) execute deal
- Total cumulative investment in the biotech firm now stands at $22 million
- Prior $8 million investment in 2024 was made via preferred stock
*this image is generated using AI for illustrative purposes only.
Natco Pharma has invested an additional $14 million in Egenesis, Inc. via its subsidiaries, raising its total investment in the US-based biotech firm to $22 million. The latest tranche was executed through convertible promissory notes, marking a shift from the equity structure of its prior investment.
Investment details
The incremental investment was made through Natco Pharma's wholly owned subsidiaries, NATCO Pharma (Canada) Inc. and NATCO Pharma South Africa Proprietary Limited. Unlike the previous investment made in 2024, which involved preferred stock, this round utilizes debt instruments with conversion options.
The following table summarises the key parameters of the new investment:
| Parameter | Details |
|---|---|
| Additional investment | $14 million |
| Instrument | Convertible promissory notes |
| Interest rate | 8% compounded annually |
| NATCO Pharma (Canada) Inc. contribution | $9.5 million |
| NATCO Pharma South Africa Prop. Ltd. contribution | $4.5 million |
| Total investment to date | $22 million |
| Previous investment (2024) | $8 million (preferred stock) |
| Investee company | Egenesis, Inc. |
About Egenesis
Egenesis, Inc. is a biotechnology company focused on creating transplantable organs through genome engineering. The company applies genetic modification techniques to develop organs intended for human transplantation, addressing a critical area within regenerative medicine.
In March 2024, eGenesis announced the world's first porcine kidney transplant in a living patient, authorized by the US FDA under the Expanded Access pathway. This was followed by two additional porcine kidney transplants with positive outcomes. The company continues to advance development programs for kidney transplant, acute liver failure, and heart transplant using its EGEN platform.
Historical Stock Returns for Natco Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.15% | -3.38% | -10.81% | -13.34% | -4.97% | -16.08% |
How might the shift from equity to convertible debt affect Natco Pharma's potential upside if Egenesis achieves a successful IPO or acquisition?
What are the specific regulatory milestones Egenesis must clear to transition its porcine organ transplant technology from Expanded Access to full FDA approval?
Could the 8% interest rate on the convertible notes signal increased perceived risk in Egenesis's near-term clinical development timeline?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
